THERAPEUTIC STUDIES--PRIMARY CNS MALIGNANCIES

恶性脑肿瘤患者的预后仍然严峻 尽管神经外科、放射治疗、神经成像和 化疗需要临床研究来评估新的治疗方法 接近。需要实验室研究为以下方面提供基础： 未来的治疗 建立一个联合体， 由临床和实验室研究人员组成的多学科团队， 几个中心的资源，将促进和加强这些所需的 问题研究 该提案描述了匹兹堡癌症中心可用的资源 研究所（PCI），匹兹堡大学，使其有资格参与 中枢神经系统联盟（CNSC）中央操作 该联盟的办公室/协调中心将设在大学 来自加州，旧金山弗朗西斯科。PCI的资源，包括 临床核心设施和组织库将提供必要的支持 用于CNSC相关试验。PC脑肿瘤中心，其临床和 实验室研究人员致力于推进脑 肿瘤患者，将与CNSC的其他成员合作， 评估新的治疗方法并研究转化研究的途径。 最初的研究将涉及评估新的药物，包括紫杉醇和 替莫唑胺，用于治疗恶性胶质瘤。今后的调查 可以包括使用O 6-烷基鸟嘌呤DNA转移酶的抑制剂， 调节肿瘤对亚硝基脲的耐药性，检查其他研究 代理商，并评估新的药物输送系统。正在进行的实验室 研究包括探索体外耐药性的调节剂， 化疗敏感性测定，脑肿瘤分化剂 治疗，脑肿瘤侵袭机制，细胞遗传学和 治疗反应和预后的分子相关性。进展 这些项目将带来创新的治疗方法， 在CNSC测试。

The prognosis for patients with malignant brain tumors remains grim despite advances in neurosurgery, radiation treatment, neuroimaging and chemotherapy. Clinical studies are needed to evaluate new treatment approaches. Laboratory research is required to provide the foundation for future therapies. The creation of a consortium, bringing together a multidisciplinary team of clinical and laboratory researchers and pooling the resources of several centers, will facilitate and enhance these needed studies. This proposal describes the resources available at the Pittsburgh Cancer Institute (PCI), University of Pittsburgh, qualifying it for participation in the Central Nervous System Consortium (CNSC). The Central Operations Office/Coordinating Center for this consortium will be at the University Of California, San Francisco. The resources of the PCI, including the Clinical Core Facility and the Tissue Bank, will provide essential support for CNSC-related trials. The PC Brain Tumor Center, with its clinical and laboratory investigators dedicated to advancing the treatment of brain tumor patients, will collaborate with other members of the CNSC to rapidly evaluate new treatments and investigate avenues of translational research. Initial studies will involve evaluating new agents, including taxol and temozolomide, in the treatment of malignant gliomas. Future investigations may include using inhibitors of O6-alkyl guanine DNA transferase to modulate tumor resistance to nitrosoureas, examining other investigational agents, and evaluating new drug delivery systems. Ongoing laboratory studies include exploring modulators of drug resistance, in vitro chemotherapy sensitivity assays, differentiation agents in brain tumor therapy, mechanisms of brain tumor invasiveness, and cytogenetic and molecular correlates of treatment response and prognosis. Advances in these projects will lead to innovative treatments that may be suitable for testing in the CNSC.